.jpeg)
2026-04-10 05:57:45
Odevixibat (Bylvay) is the first FDA-approved oral IBAT inhibitor for Progressive Familial Intrahepatic Cholestasis (PFIC) and Alagille Syndrome. By reducing bile acid reabsorption, it lowers serum levels and alleviates liver damage, offering a novel therapy for pediatric and adult patients.
2026-04-10 05:37:39
Futibatinib is a selective FGFR1-4 kinase inhibitor targeting cholangiocarcinoma with FGFR alterations. By blocking oncogenic signaling, it offers a novel treatment option for patients with refractory disease, following genetic testing confirmation.
2026-02-05 03:09:48
Luqubopar should be taken 8-14 days before a planned medical procedure, with a standard course of treatment being 3mg once daily for 7 consecutive days. Missed doses should be handled with caution, and it is not advisable to double the dose. During treatment, platelet monitoring must be regular, and medication must be administered under the guidance of a doctor.
